Yuji Itoh1, Justis P Ehlers. 1. Ophthalmic Imaging Center, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
PURPOSE: To assess outer retinal architectural alterations after intravitreal ocriplasmin with a novel automated ellipsoid zone (EZ) mapping algorithm. METHODS: A single-center, retrospective, consecutive case series of image analysis was performed. Quantitative assessment of EZ status imaged with spectral-domain optical coherence tomography was performed before and after single intravitreal injection of 0.125 mg of ocriplasmin (Jetrea, Thrombogenics). A novel EZ mapping algorithm was used to assess the EZ retinal pigment epithelium (RPE) central area, EZ-RPE macular volume, and en face EZ integrity based on the percentage of sampling areas with 20 μm or greater EZ-RPE thickness. Longitudinal assessment of these changes with custom optical coherence tomography reading software was completed. Clinical characteristics and outcomes were compared with these retinal changes. RESULTS: Nineteen eyes were included in this study. The retinal volume between EZ and RPE was significantly reduced at 1 week after ocriplasmin (P = 0.0036). Seven of 19 patients (36.8%) complained of color abnormalities or brightness reduction after injection. All of these seven patients had increased subretinal fluid after ocriplasmin and EZ attenuation. The EZ-RPE volume was reduced at 1 week (P = 0.0036), 1 month (P = 0.015) after ocriplasmin, and restored by 3 months. The area with EZ-RPE thickness below 20 μm was increased at 1 week (P = 0.046) after ocriplasmin and recovered with time. CONCLUSION: Mapping of EZ is feasible to assess EZ-RPE volume and overall EZ integrity with en face thickness mapping. Alterations in EZ occur in a significant proportion of eyes after ocriplasmin therapy. The EZ-RPE volume and the EZ-RPE central foveal area typically recover to baseline by 3 months. This effect appears to be panretinal and associated with subjective symptoms.
PURPOSE: To assess outer retinal architectural alterations after intravitreal ocriplasmin with a novel automated ellipsoid zone (EZ) mapping algorithm. METHODS: A single-center, retrospective, consecutive case series of image analysis was performed. Quantitative assessment of EZ status imaged with spectral-domain optical coherence tomography was performed before and after single intravitreal injection of 0.125 mg of ocriplasmin (Jetrea, Thrombogenics). A novel EZ mapping algorithm was used to assess the EZ retinal pigment epithelium (RPE) central area, EZ-RPE macular volume, and en face EZ integrity based on the percentage of sampling areas with 20 μm or greater EZ-RPE thickness. Longitudinal assessment of these changes with custom optical coherence tomography reading software was completed. Clinical characteristics and outcomes were compared with these retinal changes. RESULTS: Nineteen eyes were included in this study. The retinal volume between EZ and RPE was significantly reduced at 1 week after ocriplasmin (P = 0.0036). Seven of 19 patients (36.8%) complained of color abnormalities or brightness reduction after injection. All of these seven patients had increased subretinal fluid after ocriplasmin and EZ attenuation. The EZ-RPE volume was reduced at 1 week (P = 0.0036), 1 month (P = 0.015) after ocriplasmin, and restored by 3 months. The area with EZ-RPE thickness below 20 μm was increased at 1 week (P = 0.046) after ocriplasmin and recovered with time. CONCLUSION: Mapping of EZ is feasible to assess EZ-RPE volume and overall EZ integrity with en face thickness mapping. Alterations in EZ occur in a significant proportion of eyes after ocriplasmin therapy. The EZ-RPE volume and the EZ-RPE central foveal area typically recover to baseline by 3 months. This effect appears to be panretinal and associated with subjective symptoms.
Authors: Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller Journal: N Engl J Med Date: 2012-08-16 Impact factor: 91.245
Authors: Jay S Duker; Peter K Kaiser; Susanne Binder; Marc D de Smet; Alain Gaudric; Elias Reichel; SriniVas R Sadda; Jerry Sebag; Richard F Spaide; Peter Stalmans Journal: Ophthalmology Date: 2013-09-17 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Justis P Ehlers; Atsuro Uchida; Ming Hu; Natalia Figueiredo; Peter K Kaiser; Jeffrey S Heier; David M Brown; David S Boyer; Diana V Do; Andrea Gibson; Namrata Saroj; Sunil K Srivastava Journal: Ophthalmol Retina Date: 2019-07-06
Authors: Tisileli S Tuifua; Joseph R Abraham; Sunil K Srivastava; Peter K Kaiser; Jamie Reese; Justis P Ehlers Journal: Retina Date: 2022-02-01 Impact factor: 4.256
Authors: Lorenzo Iuliano; Giovanni Fogliato; Roberta Colombo; Riccardo Sacconi; Giuseppe Querques; Francesco Bandello; Marco Codenotti Journal: BMC Ophthalmol Date: 2019-05-10 Impact factor: 2.209
Authors: Touka Banaee; Rishi P Singh; Kathryn Champ; Felipe F Conti; Karen Wai; Jim Bena; Lucas Beven; Justis P Ehlers Journal: Ophthalmol Retina Date: 2018-01-06
Authors: Sruthi Arepalli; Sunil K Srivastava; Ming Hu; Peter M Kaiser; Neeley Dukles; Jamie L Reese; Justis P Ehlers Journal: PLoS One Date: 2018-10-04 Impact factor: 3.240
Authors: Kimberly A Drenser; Dante J Pieramici; Joseph M Gunn; Daniel F Rosberger; Petra Kozma; Mitchell S Fineman; Luc Duchateau; Arshad M Khanani Journal: Clin Ophthalmol Date: 2021-07-16